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Background: The need for new antibiotic drugs increases as pathogenic microorganisms continue to develop
resistance against current antibiotics. We obtained samples from Antarctica as part of a search for new antimicrobial
metabolites derived from filamentous fungi. This terrestrial environment near the South Pole is hostile and extreme
due to a sparsely populated food web, low temperatures, and insufficient liquid water availability. We hypothesize
that this environment could cause the development of fungal defense or survival mechanisms not found
elsewhere.
Results: We isolated a strain of Penicillium nalgiovense Laxa from a soil sample obtained from an abandoned
penguin’s nest. Amphotericin B was the only metabolite secreted from Penicillium nalgiovense Laxa with noticeable
antimicrobial activity, with minimum inhibitory concentration of 0.125 μg/mL against Candida albicans. This is the
first time that amphotericin B has been isolated from an organism other than the bacterium Streptomyces nodosus.
In terms of amphotericin B production, cultures on solid medium proved to be a more reliable and favorable
choice compared to liquid medium.
Conclusions: These results encourage further investigation of the many unexplored sampling sites characterized by
extreme conditions, and confirm filamentous fungi as potential sources of metabolites with antimicrobial activity.
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The lack of efficient antibiotics combined with the in-
creased spread of antibiotic-resistance genes characterize
a lingering global health problem that must be solved
[1-3]. Warnings about this problem have been frequent
and consistent, and forecasts of new resistance mecha-
nisms resulting in multiple-drug-resistant microorgan-
isms are being fulfilled [4,5].
Natural products are an important source of novel an-
tibiotics in modern medicine, and have made an unques-
tionable impact on global health so far [6-8]. Terrestrial
microbes are the sources of most known antimicrobial
compounds, but there has been a noticeable regression
in the discovery of such compounds since the 1980s [9].
This negative trend is disquieting, and highlights the need* Correspondence: ulf.goransson@fkog.uu.se
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unless otherwise stated.for improving existing sampling and screening methods of
filamentous fungi so as to advance the search for new
antimicrobial compounds [10].
Fungi have successfully survived for millions of years
under extraordinary circumstances and in varied and
challenging environments consisting of extremes in pH,
sunlight, temperature, nutrients etc. These organisms have
even survived man-made environmental impacts such as
heavy metal pollution, antibiotics, and other pharmaceut-
ically active substances. Such exposures qualify fungi as
potential sources of metabolites with differing biological
activities [11].
Fungi such as Penicillium rubens and Cephalosporium
acromonium, which produce penicillin and cephalosporin,
respectively, are prominent examples of microorganisms
used in drug discovery. Furthermore, several Trichoderma
spp. have successfully been used as fungal biocontrol
agents instead of synthetic fertilizers and pesticides [12].
The estimated 100,000 species of fungi that are knownThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that are predicted to exist, implying that fungi are an
unmapped and untapped source of secondary metabolites
with bioactive potential [13].
Unknown fungal species and their constituent metabo-
lites can be identified by investigating the microflora of
soil or biological samples from extreme or unexplored
environments. Ideally, the samples will host new micro-
bial species or novel compounds with desired activity
[14,15]. Antarctica exemplifies the environments de-
scribed above, with some of the most extreme terrestrial
conditions including low temperatures, high ice coverage
(>99%), a sparsely-populated food web, insufficient
liquid water availability, high water and airborne salinity,
and intense UV-radiation. These conditions have led to
the conclusion that microbes endure hostile surround-
ings in Antarctica, and although recent studies indicate
that this might not be the case for bacteria, it is more
likely to be true for fungi [16-20]. Limited amounts of
carbon and nitrogen substrates inhibit fungal growth in
Antarctica, even though debris from last century’s polar
expeditions have somewhat improved fungal life condi-
tions and diversified fungal flora [21].
Nonetheless, natural selection excludes any fungi that
does not adapt to the harsh environment. This raises
the question of whether new secondary metabolites with
antimicrobial activity are developed during evolutionary
competition between microbes. Earlier investigations of
soil samples from Antarctica demonstrated diversity
more often in the microbes than in their secreted
metabolites [22].
In the current work, we investigated the fungal flora
found in the extreme and rarely studied environment in
Antarctica with the aim to discover new secondary
metabolites with antimicrobial activity.
Results
Collection, cultivation and identification of Penicillium
nalgiovense Laxa
During an expedition to Antarctica in 2009, a soil
sample was collected from a penguin’s nest on Paulete
Island and transported in an unbroken freeze chain to
our laboratory in Sweden. The soil sample harbored a
large number of fungi, and one strain was chosen for
further analysis due to its strong antimicrobial activity
in the initial assays. This strain was identified at the
Fungal Cultivation Centre in the Netherlands as Penicil-
lium nalgiovense Laxa based on both genotypic charac-
ters, morphology and colony patterns. To rule out the
possibility of bacterial contamination, DNA was isolated
from the cultures of Penicillium nalgiovense Laxa and
used for PCR with universal 16S rDNA primers. No
amplicons indicating bacterial contamination could be
detected.Extraction and isolation of antimicrobial compound
The extraction of fungal cultures aimed to identify all se-
creted compounds with antimicrobial activity. Three major
extracts were analyzed: the filtrate of the liquid culture, the
mycelial growth in the liquid culture, and the cultures
growing on solid medium (Figure 1).
The filtrate of the liquid culture contained sugars and
salts (potassium chloride, sodium chloride, magnesium sul-
fate etc.), which originated from the RPMI 1640 medium.
These contents were separated from the filtrate with re-
verse phase solid phase extraction (SPE). The SPE fraction
was freeze dried, dissolved in 10% acetonitrile with 0.05%
trifluoroacetic acid (TFA), and fractionated with prepara-
tive reverse phase high performance liquid chromatog-
raphy (HPLC), yielding seven fractions (Figure 2A). The
fourth fraction included one peak with yellow color eluting
at 21.50 minutes.
The methanol (MeOH) extract from the mycelial growth
was evaporated, dissolved in 10% acetonitrile with 0.05%
TFA, and fractionated with HPLC, yielding seven fractions
(Figure 2B). The sixth fraction was yellow with a large peak
at 21.45 min, but mass spectrometry (MS) analysis showed
that it contained several substances. To separate its con-
tents, this fraction was freeze dried, dissolved in 30% aceto-
nitrile with 0.05% TFA, re-injected into an analytical HPLC
column, and fractionated with a more gradual gradient.
The MeOH extract from the solid medium cultures
had a yellow-orange color, and was fractionated with
HPLC as described above. The fourth fraction, which
originated from one large broad peak emerging at about
21 min was yellow (Figure 2C), contained several sub-
stances and was therefore fractionated again and analyzed
in the same manner as the mycelial growth extract.
Antimicrobial assays
All fractions and sub fractions were tested for antimicro-
bial activity (Figure 1). Fractions 5, 6, and 4 (Figure 2)
from the filtrate, mycelial growth extract, and solid culture
extract, respectively, all had a yellow color and showed an-
tifungal activity (MIC value 0.125 μg/mL against Candida
albicans) and weak antibacterial activity (4.0 μg/mL against
Escherichia coli and Staphylococcus aureus).
Identification and yield of amphotericin B
Reference amphotericin B was tested in the antimicrobial
assay and analyzed with HPLC, MS (Figure 3), and nuclear
magnetic resonance (NMR) spectroscopy (Figure 4) to
help identify the isolated compound. Reference amphoter-
icin B, in the form of an orange powder that turned yellow
in solution, had an identical retention time (21.50 min)
compared to the active substances in the extracts, and
produced MIC values of 0.250 μg/mL against Candida
albicans and 4.0 μg/mL against Escherichia coli and































Figure 1 Extraction procedure. Cultivation, extraction, and isolation of metabolites with antimicrobial activity from Penicillium nalgiovense Laxa.
Fractions without antimicrobial activity are marked with thinner arrows under the HPLC boxes, and those with antimicrobial activity are marked
with an asterisk (*).
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the filtrate of the liquid culture, the mycelial growth, and
the solid phase, respectively. Thus, the concentration of
amphotericin B in the 1250 mL filtrate was 80 ng/mL, and
4 μg/mL in the 50 mL mycelial growth.
The three active fractions each had a cluster of ions elut-
ing at the same time on the ultra high performance liquid
chromatography (UPLC) system (36 min 40 sec, as seen
in reference amphotericin B) with mass-charge (m/z)
ratios of 924.4989, 906.4837, and 761.4150 (Figure 3; refer-
ence amphotericin B: 924.4897 m/z, calc. 924.4952). The
first two ions were (M+H)+ and (M+H-H2O)
+, respect-
ively, and the third, (M +H-C6H12NO4)
+
, corresponds to
the loss of the mycosamine ring. The ions with m/z ratios
of 924.5 and 906.5 were analyzed with tandem MS and
generated daughter ions mainly between 650 and 762 m/z
(Figure 3). Except for ions with 761.5 m/z, the isolated
compounds had an identical set of daughter ions, indi-
cating that the parent ions with m/z ratios of 924.5 and
906.5 m/z ions originate from the same metabolite. Ref-
erence amphotericin B had identical spectra. Tandem
MS experiments with collision energies up to 80 V were
performed to detect ions with a lower m/z than 906.5,
but did not reveal more information than that alreadypresented in Figure 3. To exclude possible chemical con-
tamination, all growth media were screened for amphoter-
icin B. No amphotericin B was found.
The active fractions of amphotericin B from all
three extracts (total weight 1.5 mg) were dissolved in
dimethylsulfoxide-d6. The 1H spectra of the extract
and reference amphotericin B (Figure 4) were identical
and comparable to available NMR data from amphoteri-
cin B [23,24].
Discussion
We have isolated the antifungal secondary metabolite
amphotericin B from Penicillium nalgiovense Laxa found
in soil from a penguin’s nest in Antarctica. Isolated ampho-
tericin B was identified by comparing the solution color,
antimicrobial activity, and chromatographic, spectrometric
and spectroscopic data to those of a reference sample of
amphotericin B.
Earlier studies of Penicillium nalgiovense Laxa have
resulted in the isolation of e.g. penicillins, diaporthins,
nalgiovensin, and dipodazin [25-28]. Why amphotericin
B was not extracted from Penicillium nalgiovense Laxa
sooner when its existence has been acknowledged for
more than 80 years is unknown, but neither of earlier








Figure 2 Preparative work of fungal extracts. Chromatograms
from preparative isolation recorded at 280 nm of (A) filtrate of
liquid-based fungal culture, (B) methanol extracts of mycelial growth,
and (C) methanol extract of fungal cultures on solid medium. The
horizontal bars indicate fractionation, and the asterisks (*) indicate
antimicrobial activity. Amphotericin B eluted at 21.50 min.
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lation approaches. In those previous studies, the choice of
growth media included e.g. moistened wheat bran, the glu-
cose based Raulin-Thom solution, Czapek yeast autolysate
agar, malt extract agar, and oatmeal agar. To our know-
ledge, the current work is the first time potato dextrose
agar with coconut flakes is used for cultivation of Penicil-
lium nalgiovense Laxa. Previous extraction solvents include
petroleum, chloroform-methanol mixtures, and ethyl acet-
ate. Although amphotericin B is soluble or slightly soluble
in these solvents, none of these studies have followed the
antimicrobial activity of the extracts. Hence, our choice of
medium in combination with an assay selecting for metab-
olites with antimicrobial activity likely explains why those
earlier studies failed to detect amphotericin B.
Similarly, the same reasons could explain why we did
not detect the other Penicillium nalgiovense Laxa metab-
olites mentioned above in the current work. In addition,
comparing the results from those earlier studies demon-
strate that the variation of expressions seems highly
variable as none of them report the same set of second-
ary metabolites [25-28]. Together with the results in the
current work, it is clear that not all strains of Penicil-
lium nalgiovense Laxa produce and secrete identical sets
of metabolites, and discrepancies in fungal metabolism
could be expected.
Our cultivation procedure was noticeably improved by
using potato dextrose agar enriched with coconut flakesinstead of the liquid RPMI 1640 medium. The fungus
did usually not produce amphotericin B in liquid medium,
or sometimes no metabolites at all. In successful experi-
ments, the highest concentration of amphotericin B was
found in the 50 mL mycelial growth in the liquid culture
at a concentration of 4 μg/mL to a total mass of 0.2 mg.
Cultures based on solid media generated an overall better
yield, as we repeatedly managed to extract amphotericin B
from the first cultivation attempt and in larger amounts
during a shorter period of time. A culture the size of 40
petri dishes (24,5 dm2) rendered a total mass of 1.2 mg
amphotericin B, thus this method was consider more
favorable, since it was cheaper, quicker, and more reliable
in terms of metabolic production.
Amphotericin B is an antifungal agent used worldwide
against fungal infections since 1959 [29]. It is prescribed
against infections caused by microbes including Candida
spp., Aspergillus spp., Leishmania spp., [30,31] and zygo-
mycetes, but is not used against bacteria, since it has no,
or limited, antibacterial activity [32]. It was discovered in
1955 when isolated from a strain of Streptomyces nodo-
sus found in a soil sample from the Orinoco River in
northern South America. The activity of amphotericin B
is caused by its affinity to ergosterol, which is a principal
sterol in fungal cell membranes. Amphotericin B acts by
binding to ergosterol and creating a pore, with the polyene
side oriented towards the membrane [33]. Through this
pore, ions and small molecules can leak in and out of the
cell, which causes metabolic disruption and eventually cell
death [34,35]. The extracts in this study showed activity
against Candida albicans, which is expected of amphoter-
icin B, but also demonstrated weak antibacterial activity
against Escherichia coli and Staphylococcus aureus. This
is unexpected since ergosterol, to which amphotericin B
binds, is present in neither bacterial cell walls nor mem-
branes [32].
So far, there are no reports of other organisms, except
Streptomyces nodosus, producing amphotericin B [36,37].
Amphotericin B is biosynthesized in Streptomyces nodosus
by the genes amphA-C, amphDI-III, amphG-N, and three
open reading frame genes [29]. Although this study did
not investigate the biosynthetic mechanism for the
production of amphotericin B in Penicillium nalgiovense
Laxa, it could be explained by a lateral gene transfer
from Streptomyces nodosus or another organism able to
produce amphotericin B. If not, a different biosynthetic
mechanism may have been developed independently by
either this strain of Penicillium nalgiovense Laxa or by
the genus itself. It can also be argued that dormant genes
in this organism need specific activation cues to produce
secondary metabolites with or without antimicrobial activ-
ity. Since the genes of Penicillium nalgiovense Laxa are
still not mapped, this remains unclear and is considered a
field of future studies.
Figure 3 Identification of amphotericin B. The preparative and analytical results of the experiments identifying the only substance with
antimicrobial activity in a culture extract of Penicillium nalgiovense Laxa. The methanol extracts of the mycelial growth and liquid filtrate were
fractionated with HPLC (bottom two chromatograms recorded at 280 nm), analyzed with Q-TOF MS (middle spectra), and compared with the
reference substance amphotericin B (top figure). Identical elution times (21 minutes 50 seconds), mother ions (924.4989 and 906.4837 m/z), and
daughter ions (743.5, 761.5 m/z) between the extracted compound and reference amphotericin B, together with NMR analysis and antimicrobial
assays, led to the identification of amphotericin B in the fungal extracts.
1.02.03.04.05.06.0
ppm
Figure 4 1H NMR spectra of extract (below) and reference
amphotericin B (above) dissolved in dimethylsulfoxide-d6.
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was discovered and classified in 1932 by O. Laxa and is
used today in the food industry as a starting culture for
sausages, generating their white-greyish colored cover
[27]. To date, with the exception of penicillin and some
peptaibols (peptides consisting of five to 20 amino acids,
including the unusual amino acid alpha-aminoisobutyric
acid, and a C-terminal alcohol), there are no reports of
antimicrobial metabolites being produced by Penicillium
nalgiovense Laxa, thus making it suitable for the food
industry [38]. Even the most common fungal toxins are
not produced by Penicillium nalgiovense Laxa, except in
a few cases for some strains [25,26,39,40]. A fungus
cultured on a sausage might not necessarily produce the
same set of metabolites as it would in a laboratory, but
our results show that the current use of Penicillium
nalgiovense Laxa in food production may be taken under
Svahn et al. Fungal Biology and Biotechnology  (2015) 2:1 Page 6 of 8consideration, since amphotericin has activity against
eukaryotic organisms.
Fungi have a history of being rich in production of
secondary metabolites of various types with a wide range
bioactivity, which have been the source of a number of
pharmaceutically useful drugs [41]. In the search for
metabolites with novel structures and activity, diverse
terrestrial and marine environments have continuously
being screened [8,42]. One of the least explored sites in
this regard is Antarctica. This continent offers a hostile
environment for any organism with e.g. low temperature,
sparsely distributed water, and limited food web, and is
relatively difficult to approach in the screening for bio-
active compounds originating from microorganisms. Col-
lections on this location are expensive and cumbersome
compared to almost any other and studies of the micro
flora and bioactive compounds have so far been few [22].
This is the first time Penicillium nalgiovense Laxa have
been isolated from Antarctica.
Even though this fungus species belongs to as well-
studied a genus as Penicillium, and has been known and
cultivated for more than 80 years, investigational ap-
proaches that involve searching new environments for
new antibiotic metabolites demonstrate that known fungi
still have unmapped metabolism and deserve more in-
depth studies.
Conclusions
This study has shown that a strain of Penicillium nalgio-
vense Laxa can produce the antifungal metabolite ampho-
tericin B, which was more favorably produced when the
fungus was cultivated on solid, rather than in liquid media.
The fungus was isolated from a soil sample found in a
penguin’s nest in Antarctica, which provides an extreme
and hostile environment. Penicillium nalgiovense Laxa is
the second organism, after Streptomyces nodosus, reported
to produce this metabolite. This work demonstrates the
value of natural product extraction from filamentous
fungi, even from a well-studied genus like Penicillium, and
suggests further investigation of unexplored sampling sites
characterized by extreme conditions.
Methods
Chemicals
All water was filtered through an A10 0.22 μm Millipore
filter (Merck Millipore, Billerica, MA), unless otherwise
stated. Extraction and chromatography was performed
using acetonitrile (VWR, Radnor, PE), trifluoroacetic acid
(IRIS Biotech, Marktredwitz, GER), and MeOH (Merck,
Darmstadt, GER). The MS analysis was carried out with
water, formic acid, and acetonitrile (Sigma Aldrich, St Louis,
MO), and NMR spectroscopy with dimethylsulfoxide-d6
(Armar Chemicals, Döttingen, SWI). Reference amphoteri-
cin B was purchased from Abcam (Cambridge, UK).Fungal collection, cultivation, identification, and PCR
analysis
A soil sample from a recently abandoned Adélie Penguin
(Pygoscelis adeliae) nest located on Paulete Island (63°
35′ 0″ S, 55° 47′ 0″ W) on Antarctica was collected in a
tube containing cryo-protective broth. The sample was
frozen at -70°C and transported in an unbroken freeze
chain to the Department of Clinical Microbiology at
Karolinska University Laboratory in Stockholm, Sweden.
The sample was cultured onto Sabouraud dextrose agar
(Oxoid, Hampshire, UK), which was incubated at room
temperature until colonies were visible. A large number
of molds were isolated from the sample. The Penicillium
sp. strain, which showed the strongest antibiotic activity
in initial assays, was chosen for this study.
The strain was identified as Penicillium nalgiovense
Laxa at the Fungal Biodiversity Center in the Netherlands.
The fungus was cultured on malt extract agar, oatmeal
agar, synthetic nutrient agar and dichloran 18% glycerol
agar. DNA was extracted from the malt extract agar plate
after an incubation period of 3 days in the dark at 25°C
using the MoBio - UltraClean Microbial DNA Isolation
Kit. Fragments containing of part of the alpha-tubulin
gene was performed using the primers Bt2a (GGTAAC
CAAATCGGTGCTGCTTTC) and Bt2b (ACCCTCAGT
GTAGTGACCCTTGGC) [43]. The PCR fragments were
sequenced with the ABI Prisma Big DyeTM Terminator v.
3.0 Ready Reaction Cycle sequencing Kit. Samples were
analyzed on an ABI PRISM 3700 Genetic Analyzer and
contigs were assembled using the forward and reverse
sequences with the program SeqMan from the Laser-
Gene package. The sequences were compared on
GenBank using BLAST and in a large fungal database of
CBS-KNAW Fungal Biodiversity Centre with sequences
of most of the type strains. The results had a 100%
match in all databases with the type strain of Penicil-
lium nalgiovense Laxa.
PCR analysis at Uppsala University was performed
with a High Pure PCR Template Preparation Kit version
19 (Roche, Basel, CH) according to manufacturer’s in-
structions. Regions within 16S rDNA genes were ampli-
fied by PCR using purified nucleic acids as a template,
and primers (5′ - 3′) E341F: CCTACGGGNGGCNGCA
and E1406R: GACGGGCGGTGWGTRCA [44]. The PCR
products were analyzed using a MultiNA (Shimadzu,
Kyoto, JPN) according to manufacturer’s instructions.
An Eppendorf Mastercycler (Eppendorf, Hamburg, GER)
was used for 16S rDNA amplification with the following
PCR conditions: initial denaturing step: 95°C for 5 min;
amplification: 40 cycles of denaturation at 94°C for 30 sec,
annealing at 59°C for 30 sec and elongation at 74°C for
1 min; final elongation step: 74°C for 10 min.
Two different attempts to cultivate the isolated fungus
Penicillium nalgiovense Laxa were made: in liquid and
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collected from Sabouraud dextrose agar were suspended
in 1300 mL RPMI 1640 liquid medium (Sigma Aldrich, St
Louis, MO) with pH 7.2 to reach a concentration of 4 –
6 × 108 conidia per mL. The culture was divided into 33
Falcon tubes and incubated under static and aerobic
conditions at 20°C. After 14 days, the mycelial growth
and the liquid medium were separated by paper filtra-
tion (Munktell, Falun, SWE). For the second attempt,
conidia were dispersed on forty petri dishes (9 cm in
diameter corresponding to a total area of 25,4 dm2) with
potato-dextrose agar (pH 5.6) mixed with coconut flakes
to enrich nutrient content [45,46]. The cultures were in-
cubated for seven days at 20°C under static and aerobic
conditions. Both cultivation attempts were carried out
in the dark and aerobic conditions were ensured with
slightly open lids.
Extraction and preparative HPLC
The filtrates of the liquid cultures were separated with
SPE, using C18 columns with 10 g packing material
(Biotage, Uppsala, SWE). The columns were condi-
tioned with MeOH for 1 hour and equilibrated with
10% acetonitrile and 0.05% TFA. Sixty mL of filtrate
was added to each column, eluted with 40 mL of 80%
acetonitrile with 0.05% TFA, evaporated, and dissolved
in 80 mL 10% acetonitrile with 0.05% TFA. The myce-
lial growth residue was subjected to extraction with
100 mL MeOH three times. Metabolites from the forty
fungal cultures on solid medium were extracted with
10 mL MeOH each for 10 minutes. The two MeOH
extracts were evaporated in a speed vacuum centrifuge
(Speed Vac Plus SC110 A, Savant Instrument, NY) and
dissolved in 20 mL (mycelial growth extract) or 50 mL
(extract from solid medium cultures) 10% acetonitrile
with 0.05% TFA.
Preparative isolation was carried out using an ÄKTA
Basic 10 HPLC system (Amersham Pharmacia Biotech,
Sweden) with a C18 250 × 10 mm, 5 μm Jupiter column
(Phenomenex, Torrance, CA). The UV-900 detector
operated at 210 nm, 254 nm, and 280 nm, and the P-490
pump was set to 5 mL/min. Eluent A and B were 10%
acetonitrile and 60% acetonitrile, respectively, both with
0.05% TFA. After 5 minutes of isocratic 0% eluent B, the
gradient was increased to 100% B within 44 minutes.
Some fractions that contained several substances needed
further preparative work. Those fractions were freeze
dried and dissolved in 5 mL 30% acetonitrile with 0.05%
TFA, and injected into a C18 250 × 4.6 mm, 5 μm
Jupiter analytical column (Phenomenex, Torrance, CA)
on the same ÄKTA HPLC system and with the same
eluents. The gradient was adjusted to isocratic 30%
eluent B for 5 minutes, and then increased to 100% B
during 120 minutes.Antimicrobial assays
Assays for antimicrobial activity and MIC assays were
carried out as reported earlier against Escherichia coli
ATCC 25922, Staphylococcus aureus ATCC 29213, Pseudo-
monas aeruginosa ATCC27853, and Candida albicans
ATCC 90028 [11], or according to international standard-
ized protocol [47].
Structure determination of isolated compound
The fractions that showed antimicrobial activity were
analyzed with a Nano Acquity UPLC system coupled to a
quadropole time-of-flight mass spectrometer (Qtof Micro,
Waters, Milford, MA). During MS analysis the capillary
voltage was 4100 V, sample cone 30 V, and the collision
energy was set to 5 V, but increased to 15, 25, 40, 55, and
65 V with a 1 second interscan time during MS/MS
analysis. The column was a C18 Nano Acquity 75 μm×
250 mm column with 1.7 μm particle size (Waters,
Milford, MA). The lock mass was a 1.27 μM solution of
(Glu1)-Fibrinopeptide B (Sigma Aldrich, St Louis, MO),
infused at a flow rate of 0.4 μL/min. All spectra and
chromatograms were analyzed with MassLynx version 4.0
software package. The two eluents: A and B, were water
and acetonitrile, respectively, with 0.1% formic acid at a
flow rate of 0.250 μL/min. All samples were injected and
separated on the column with an isocratic step of 1% B for
1 minute, and a gradient increasing to 90% B during 49 mi-
nutes, and held for 4 minutes. To avoid possible microbial
growth in eluent A, 0.05% MeOH was added.
1H NMR experiments were performed on a Bruker
600 MHz spectrometer equipped with a smartprobe,
using tetramethylsilane as internal standard. All samples
were dissolved in 99.9% dimethylsulfoxide-d6 and
analyzed at 25°C.
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